Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.54% | -22.25% | 8.91% | -21.82% | -51.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.54% | -22.25% | 8.91% | -21.82% | -51.09% |
| Cost of Revenue | 4.30% | -13.08% | 38.98% | -22.56% | -51.77% |
| Gross Profit | 29.04% | -28.51% | -11.59% | -21.42% | -50.37% |
| SG&A Expenses | 11.26% | 0.68% | 6.49% | -7.42% | 0.42% |
| Depreciation & Amortization | -18.61% | -20.39% | 2.99% | 0.32% | 2.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.18% | -6.49% | 18.76% | -11.56% | -27.21% |
| Operating Income | 16.54% | -353.63% | -210.72% | -119.72% | -1,110.40% |
| Income Before Tax | 20.53% | -383.70% | -486.98% | -93.50% | -739.33% |
| Income Tax Expenses | -- | -- | -- | 142.92% | -- |
| Earnings from Continuing Operations | 20.53% | -223.47% | -130.08% | -112.71% | -739.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.53% | -223.47% | -130.08% | -112.71% | -739.33% |
| EBIT | 16.54% | -353.63% | -210.72% | -119.72% | -1,110.40% |
| EBITDA | 15.76% | -587.65% | -349.61% | -80.86% | -298.91% |
| EPS Basic | 15.99% | -237.86% | -139.39% | -112.91% | -751.39% |
| Normalized Basic EPS | 16.04% | -431.71% | -604.76% | -93.45% | -751.11% |
| EPS Diluted | 15.99% | -254.37% | -139.39% | -116.90% | -751.39% |
| Normalized Diluted EPS | 16.04% | -431.71% | -604.76% | -93.37% | -751.11% |
| Average Basic Shares Outstanding | -5.38% | -4.38% | -3.65% | -1.98% | -1.26% |
| Average Diluted Shares Outstanding | -5.38% | -4.38% | -3.65% | -3.17% | -2.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
